However, a drug that belongs to a group of medicines called SGLT2 inhibitors has not shown statistically significant benefits to prevent cardiac arrest or stroke, including in patients with diagnosed cardiovascular disease.
Diabetics have an increased risk of heart problems, which makes cardiovascular drugs beneficial from the attention of doctors and patients.
Stephen Wiviott of Brigham and Boston Women's Hospital, a senior researcher in this cynical study, said these findings were important in a clear picture of SGLT2, which has so far been addressed to patients diagnosed with carcasses.
AstraZeneca hopes that new data will help expand the use of Farxiga to a wider range of patients.
The main results of a clinical study, which show up on the cohort of 17,000 patients, were first published in September, and details were disclosed on Saturday at the annual American Heart Association meeting and were published at the same time in the New England Journal of Medicine.
These results showed that Farxiga reduced by 27% the risk of hospitalization due to a heart problem, as well as the risk of developing renal disease.
While two smaller studies involving competing SGLT2 drugs focused on patients with diagnosed heart disease, Wiviott said that the overall picture of the reported study showed that the main advantage was the prevention of heart attacks.
"When we analyze three studies, it is clear that the primary benefit of this class of cardiovascular drugs is to reduce heart failure," said Wiviott.
Diabetics for decades have been focusing mainly on reducing blood glucose levels at certain levels. But diabetics' preconceptions to other issues, such as heart failure, where the five-year survival rate is only 50%, suggests that a more holistic approach is needed, says Wiviott.
"The message right now is to reduce the level of glucose as important as the share we are doing. We need to choose drugs that improve the expected life of patients, not just drugs that have an effective reduction in blood glucose," said the doctor.
Farxiga competes with SGLT2 competing products, including Jardiance, manufactured by Eli Lilly and Boehringer Ingelheim, and Invokana Johnson & Johnson, who have already shown prolonged life for patients with diagnosed cardiac problems, a so-called secondary prevention.
Because AstraZeneca studies have also assessed patients without a cardiovascular disease diagnosis, this study opens a wider market that includes primary prevention.
The Declare study did not show an increased risk of amputations, fractures, bladder cancer or gangrene in patients treated with Farxiga, problems occasionally observed in patients treated with SGLT but increased genital infection.